JP2003520763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520763A5 JP2003520763A5 JP2000598059A JP2000598059A JP2003520763A5 JP 2003520763 A5 JP2003520763 A5 JP 2003520763A5 JP 2000598059 A JP2000598059 A JP 2000598059A JP 2000598059 A JP2000598059 A JP 2000598059A JP 2003520763 A5 JP2003520763 A5 JP 2003520763A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- disease
- hmg1
- antagonist
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 description 13
- 101150091750 HMG1 gene Proteins 0.000 description 12
- 102000055207 HMGB1 Human genes 0.000 description 12
- 108700010013 HMGB1 Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 101100178203 Arabidopsis thaliana HMGB3 gene Proteins 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 101150021904 HMGB1 gene Proteins 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 206010058872 Fungal sepsis Diseases 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010062164 Seronegative arthritis Diseases 0.000 description 1
- 208000009714 Severe Dengue Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 206010044251 Toxic shock syndrome streptococcal Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/248,574 US6303321B1 (en) | 1999-02-11 | 1999-02-11 | Methods for diagnosing sepsis |
| US09/248,574 | 1999-02-11 | ||
| PCT/US2000/003583 WO2000047104A2 (en) | 1999-02-11 | 2000-02-11 | Antagonists of hmg1 for treating inflammatory conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011058031A Division JP5745299B2 (ja) | 1999-02-11 | 2011-03-16 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520763A JP2003520763A (ja) | 2003-07-08 |
| JP2003520763A5 true JP2003520763A5 (enExample) | 2010-09-16 |
| JP4812166B2 JP4812166B2 (ja) | 2011-11-09 |
Family
ID=22939703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000598059A Expired - Lifetime JP4812166B2 (ja) | 1999-02-11 | 2000-02-11 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
| JP2011058031A Expired - Lifetime JP5745299B2 (ja) | 1999-02-11 | 2011-03-16 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
| JP2013241528A Pending JP2014031386A (ja) | 1999-02-11 | 2013-11-22 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011058031A Expired - Lifetime JP5745299B2 (ja) | 1999-02-11 | 2011-03-16 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
| JP2013241528A Pending JP2014031386A (ja) | 1999-02-11 | 2013-11-22 | 炎症症状を治療するためのｈｍｇ１のアンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (12) | US6303321B1 (enExample) |
| EP (4) | EP1707214A1 (enExample) |
| JP (3) | JP4812166B2 (enExample) |
| AT (1) | ATE327764T1 (enExample) |
| AU (1) | AU782984B2 (enExample) |
| CA (1) | CA2359926C (enExample) |
| DE (1) | DE60028358T3 (enExample) |
| DK (1) | DK1165110T3 (enExample) |
| ES (1) | ES2269118T5 (enExample) |
| PT (1) | PT1165110E (enExample) |
| WO (1) | WO2000047104A2 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387639B1 (en) * | 1998-11-10 | 2002-05-14 | Sloan-Kettering Institute For Cancer Research | Ma family polypeptides and anti-Ma antibodies |
| US6303321B1 (en) † | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US20060154319A1 (en) * | 1999-04-29 | 2006-07-13 | Flodgaard Hans J | Inhibition of bradykinin release |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| HUP0500042A3 (en) * | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| US7220723B2 (en) * | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| JP5055598B2 (ja) * | 2001-07-13 | 2012-10-24 | 株式会社シノテスト | ヒトｈｍｇ−１に特異的に結合する抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬 |
| ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| US7465555B2 (en) * | 2002-04-02 | 2008-12-16 | Becton, Dickinson And Company | Early detection of sepsis |
| ATE424416T1 (de) | 2002-07-03 | 2009-03-15 | San Raffaele Centro Fond | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| JP2005532056A (ja) * | 2002-07-05 | 2005-10-27 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | ミトコンドリア核酸の測定法を用いる敗血症の診断 |
| GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| MXPA05005073A (es) * | 2002-11-12 | 2005-11-17 | Becton Dickinson Co | Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. |
| MXPA05005072A (es) * | 2002-11-12 | 2005-07-22 | Becton Dickinson Co | Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. |
| CA2505921A1 (en) * | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| US20040141948A1 (en) * | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| NZ540067A (en) * | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
| US20040156851A1 (en) * | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| AU2003295653B2 (en) * | 2002-11-20 | 2007-08-16 | The Feinstein Institute Of Medical Research | Use of HMGB polypeptides for increasing immune responses |
| JP4750421B2 (ja) | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
| EP1601969A2 (en) | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
| US7892745B2 (en) | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US20090069227A9 (en) * | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
| FR2855832B1 (fr) * | 2003-06-03 | 2007-09-14 | Biomerieux Sa | Procede de diagnostic et/ou de pronostic d'un syndrome septique |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2882022A1 (en) * | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| WO2005028512A1 (en) * | 2003-09-19 | 2005-03-31 | Leukotech A/S | Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp) |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| EP1673465A4 (en) * | 2003-09-29 | 2008-04-30 | Biosite Inc | PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS |
| US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| CA2560756A1 (en) | 2004-03-25 | 2005-10-06 | The Feinstein Institute For Medical Research | Methods and devices for reducing bleed time using vagus nerve stimulation |
| US20080305120A1 (en) * | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| EP1814576A2 (en) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| EP1797118A2 (en) * | 2004-09-03 | 2007-06-20 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| US7645575B2 (en) * | 2004-09-08 | 2010-01-12 | Xdx, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
| US20080050832A1 (en) * | 2004-12-23 | 2008-02-28 | Buechler Kenneth F | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| AU2005323463B2 (en) | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| US20060157647A1 (en) * | 2005-01-18 | 2006-07-20 | Becton, Dickinson And Company | Multidimensional liquid chromatography/spectrometry |
| ITRM20050032A1 (it) * | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
| FR2881437B1 (fr) | 2005-01-31 | 2010-11-19 | Biomerieux Sa | Procede pour le diagnostic/pronostic d'un syndrome septique |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| WO2006124477A2 (en) * | 2005-05-13 | 2006-11-23 | The Feinstein Institute For Medical Research | Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases |
| WO2006138429A2 (en) | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
| WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| US20100040608A1 (en) * | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
| WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
| JP3876325B1 (ja) | 2005-10-24 | 2007-01-31 | 国立大学法人 岡山大学 | 脳梗塞抑制剤 |
| US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
| CA2631212A1 (en) * | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| US7829097B2 (en) | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
| US7986727B2 (en) * | 2006-03-28 | 2011-07-26 | Globalfoundries Inc. | In-band method to configure equalization levels |
| US8570881B2 (en) * | 2006-03-28 | 2013-10-29 | Advanced Micro Devices, Inc. | Transmitter voltage and receiver time margining |
| JP3882090B1 (ja) | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
| WO2008021431A2 (en) | 2006-08-14 | 2008-02-21 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders |
| EP2065432B2 (en) † | 2006-09-20 | 2017-10-25 | Asahi Kasei Kabushiki Kaisha | Polyolefin microporous membrane and separator for nonaqueous electrolyte battery |
| EP2102367A2 (en) | 2006-11-09 | 2009-09-23 | XDX, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| TW200846366A (en) * | 2007-02-15 | 2008-12-01 | Univ Fukuoka | Agent for suppressing rejection in organ transplantation comprising anti-hmgb-1 antibody |
| US8470325B2 (en) * | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
| JP5241518B2 (ja) * | 2007-02-15 | 2013-07-17 | 国立大学法人九州大学 | 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤 |
| US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US20100255513A1 (en) * | 2007-03-30 | 2010-10-07 | Denson Lee A | Serological markers of inflammatory bowel disease phenotype and disease progression |
| GB0711327D0 (en) | 2007-06-12 | 2007-07-25 | Hansa Medical Ab | Diagnostic method |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| US20090208513A1 (en) * | 2007-09-07 | 2009-08-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions |
| JP5224325B2 (ja) * | 2007-10-15 | 2013-07-03 | 国立大学法人 岡山大学 | Ｂ細胞悪性リンパ腫治療薬 |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| WO2009123737A2 (en) | 2008-04-03 | 2009-10-08 | Becton, Dickinson And Company | Advanced detection of sepsis |
| US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| JP2012513591A (ja) * | 2008-12-22 | 2012-06-14 | ザ チルドレンズ リサーチ インスティテュート | 敗血症の検出のための方法 |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| US20110123483A1 (en) * | 2009-11-23 | 2011-05-26 | Deutsches Krebsforschungszentrum | Hmgb1 for cancer treatment |
| US20110217301A1 (en) * | 2009-12-22 | 2011-09-08 | The Children's Research Instute | Methods for treating or screening for compounds for the treatment of sepsis |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| DK2365332T3 (da) * | 2010-03-10 | 2013-08-26 | Pasteur Institut | HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser |
| WO2011123396A1 (en) | 2010-03-29 | 2011-10-06 | University Of Southern California | Compositions and methods for the removal of biofilms |
| JP5786020B2 (ja) | 2010-04-16 | 2015-09-30 | アボットジャパン株式会社 | 関節リウマチを診断する方法および試薬 |
| IT1406051B1 (it) * | 2010-08-05 | 2014-02-06 | D M G Italia S R L | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| AU2011299025B2 (en) * | 2010-09-09 | 2015-07-09 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| GB201016161D0 (en) | 2010-09-24 | 2010-11-10 | Hansa Medical Ab | Diagnostic method |
| GB201102108D0 (en) | 2011-02-07 | 2011-03-23 | Hansa Medical Ab | Diagnostic method |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| DK3369742T3 (da) * | 2011-10-05 | 2020-10-19 | Univ Rockefeller | Dimere bakteriofaglysiner |
| US20130171659A1 (en) * | 2011-12-28 | 2013-07-04 | Abbott Japan Co., Ltd. | Methods of prognosis and diagnosis of rheumatoid arthritis |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US20150335763A1 (en) * | 2013-01-09 | 2015-11-26 | The Feinstein Institute For Medical Research | Hmgb1-binding beads and uses thereof |
| MX2015009547A (es) | 2013-01-28 | 2015-11-25 | Evec Inc | Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo. |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US9840555B2 (en) | 2013-11-04 | 2017-12-12 | Li-Te Chin | Method for producing human monoclonal antibodies that binds to at least one part of HMGB1 |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| HK1255383A1 (zh) | 2015-07-31 | 2019-08-16 | The Research Institute At Nationwide Children's Hospital | 去除生物膜的肽及抗體 |
| US11274132B2 (en) | 2015-12-11 | 2022-03-15 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| EP3595445B1 (en) | 2017-03-15 | 2024-09-04 | The Research Institute at Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| EP3860718A4 (en) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL |
| JP7313659B2 (ja) * | 2019-03-12 | 2023-07-25 | 株式会社シノテスト | 試料中のｈｍｇｂ１の測定方法及び測定試薬 |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| CA3139109A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
| IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| CN119936405A (zh) * | 2025-01-23 | 2025-05-06 | 上海市重大传染病和生物安全研究院 | 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678772A (en) | 1983-02-28 | 1987-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing glycyrrhizin |
| JPS6032714A (ja) | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
| US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
| JPS63135351A (ja) | 1986-11-28 | 1988-06-07 | Sanwa Kagaku Kenkyusho Co Ltd | グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2998287B2 (ja) | 1991-03-13 | 2000-01-11 | 千寿製薬株式会社 | グリチルレチン酸誘導体 |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| IT1253431B (it) | 1991-12-02 | 1995-08-08 | Valetudo S R L | Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica |
| IT1254321B (it) | 1992-04-10 | 1995-09-14 | Kemiprogress S R L | Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale. |
| GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
| EP0727487A1 (en) † | 1995-02-17 | 1996-08-21 | K.U. Leuven Research & Development | Multiple-tumor aberrant growth genes |
| JP3472048B2 (ja) | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
| US6323329B1 (en) * | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
| DE19548122A1 (de) | 1995-12-21 | 1997-06-26 | Joern Prof Dr Bullerdiek | Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
| US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
| EP1577671A1 (en) * | 1996-07-17 | 2005-09-21 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| WO2000020621A1 (en) | 1998-10-06 | 2000-04-13 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| EP1798288B1 (en) | 1997-05-07 | 2009-09-16 | Schering Corporation | Human Toll-like receptor proteins, related reagents and methods |
| IT1291366B1 (it) | 1997-05-14 | 1999-01-07 | Angelini Ricerche Spa | Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale |
| US20030027260A1 (en) | 1997-10-17 | 2003-02-06 | Genentech, Inc. | Human Toll homologues |
| ATE463502T1 (de) | 1997-10-17 | 2010-04-15 | Genentech Inc | Menschliche toll-homologe |
| ES2137125B1 (es) | 1997-11-18 | 2000-08-16 | Vinyals S A Lab Dr | La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. |
| US6783961B1 (en) | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| TWI221082B (en) | 1999-04-14 | 2004-09-21 | Sumitomo Chemical Co | Pesticidal compositions |
| EP1187932A2 (en) | 1999-06-04 | 2002-03-20 | Millennium Pharmaceuticals, Inc. | Mammalian toll homologues and uses thereof |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| GB9927332D0 (en) | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
| US6677321B1 (en) | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| GB0001704D0 (en) | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Protein |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001244711A1 (en) | 2000-03-31 | 2001-10-08 | Mochida Pharmaceutical Co., Ltd. | Tlr/cd14 binding inhibitor |
| JP2001322276A (ja) * | 2000-05-15 | 2001-11-20 | Fuji Xerox Co Ltd | インクジェット記録ヘッド、インクジェット記録装置及びヘッド作製方法 |
| CN1721443A (zh) | 2000-05-25 | 2006-01-18 | 先灵公司 | 人受体蛋白；相关的试剂和方法 |
| US7361678B2 (en) | 2002-03-05 | 2008-04-22 | Transtech Pharma, Inc. | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents |
| GB0015325D0 (en) | 2000-06-22 | 2000-08-16 | Danionics As | Electrochemical cells |
| AU2002306651B2 (en) | 2001-03-02 | 2007-12-13 | Medimmune, Llc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists |
| AU2002245590B2 (en) | 2001-03-05 | 2006-06-29 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| AU2002245591B2 (en) | 2001-03-05 | 2007-05-17 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
| JP2004528307A (ja) | 2001-03-15 | 2004-09-16 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 |
| ITMI20010562A1 (it) | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| WO2002089743A2 (en) | 2001-05-09 | 2002-11-14 | The Regents Of The University Of Michigan | Use of compositions for treating rosacea |
| CA2446458A1 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| HUP0500042A3 (en) | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| JP4823465B2 (ja) | 2001-07-13 | 2011-11-24 | 株式会社シノテスト | ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬 |
| US20030032674A1 (en) | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
| CN1575184A (zh) | 2001-09-07 | 2005-02-02 | 波士顿大学理事会 | 治疗免疫复合物相关疾病的方法和组合物 |
| JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長ｃＤＮＡ |
| EP1293566A1 (en) | 2001-09-17 | 2003-03-19 | Societe Des Produits Nestle S.A. | A soluble toll-like receptor |
| US20050118688A1 (en) | 2001-12-28 | 2005-06-02 | Hudson Freeze | Novel ligand involved in the transmigration of leukocytes across the endothelium and uses therefor |
| ATE424416T1 (de) | 2002-07-03 | 2009-03-15 | San Raffaele Centro Fond | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| NZ540067A (en) | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
| AU2003295653B2 (en) | 2002-11-20 | 2007-08-16 | The Feinstein Institute Of Medical Research | Use of HMGB polypeptides for increasing immune responses |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7807696B2 (en) | 2003-10-07 | 2010-10-05 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
| US20090062187A1 (en) | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
| MX2007001559A (es) | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| EP1797118A2 (en) | 2004-09-03 | 2007-06-20 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
| US20100040608A1 (en) | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
| AU2006312847A1 (en) | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting HMGB1 |
| CA2631212A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| MY161894A (en) | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| WO2008076758A2 (en) * | 2006-12-13 | 2008-06-26 | William Marsh Rice University | Nerolidol, terpene, and terpene derivative synthesis |
| US20100249038A1 (en) | 2007-06-12 | 2010-09-30 | Board Of Regents, University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
-
1999
- 1999-02-11 US US09/248,574 patent/US6303321B1/en not_active Expired - Lifetime
-
2000
- 2000-02-11 EP EP05077852A patent/EP1707214A1/en not_active Withdrawn
- 2000-02-11 ES ES00915762.9T patent/ES2269118T5/es not_active Expired - Lifetime
- 2000-02-11 DK DK00915762T patent/DK1165110T3/da active
- 2000-02-11 CA CA2359926A patent/CA2359926C/en not_active Expired - Lifetime
- 2000-02-11 DE DE60028358.5T patent/DE60028358T3/de not_active Expired - Lifetime
- 2000-02-11 EP EP20100075469 patent/EP2362221A1/en not_active Ceased
- 2000-02-11 AU AU36983/00A patent/AU782984B2/en not_active Expired
- 2000-02-11 EP EP00915762.9A patent/EP1165110B2/en not_active Expired - Lifetime
- 2000-02-11 WO PCT/US2000/003583 patent/WO2000047104A2/en not_active Ceased
- 2000-02-11 PT PT00915762T patent/PT1165110E/pt unknown
- 2000-02-11 AT AT00915762T patent/ATE327764T1/de active
- 2000-02-11 JP JP2000598059A patent/JP4812166B2/ja not_active Expired - Lifetime
- 2000-02-11 EP EP06075291.2A patent/EP1757937B1/en not_active Expired - Lifetime
- 2000-02-14 US US09/503,632 patent/US6468533B1/en not_active Expired - Lifetime
-
2001
- 2001-08-15 US US09/929,962 patent/US6448223B1/en not_active Expired - Lifetime
-
2002
- 2002-07-31 US US10/210,747 patent/US7097838B2/en not_active Expired - Lifetime
- 2002-09-11 US US10/242,056 patent/US7060504B2/en not_active Expired - Fee Related
-
2005
- 2005-12-01 US US11/292,320 patent/US7537908B2/en not_active Expired - Fee Related
-
2006
- 2006-06-29 US US11/477,835 patent/US7572446B2/en not_active Expired - Fee Related
-
2009
- 2009-04-13 US US12/386,053 patent/US8053206B2/en not_active Expired - Fee Related
- 2009-07-01 US US12/496,333 patent/US8138141B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 JP JP2011058031A patent/JP5745299B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-22 US US13/402,057 patent/US8822169B2/en not_active Expired - Fee Related
-
2013
- 2013-11-22 JP JP2013241528A patent/JP2014031386A/ja active Pending
-
2014
- 2014-08-29 US US14/473,333 patent/US20150322140A1/en not_active Abandoned
-
2016
- 2016-01-21 US US15/002,688 patent/US20170129946A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520763A5 (enExample) | ||
| JP2005512507A5 (enExample) | ||
| US7138496B2 (en) | Human monoclonal antibodies against human CXCR4 | |
| RU2006101702A (ru) | Антитела против интерлейкина-22 и их применения | |
| JP2008509227A5 (enExample) | ||
| US20090022726A1 (en) | Method of using il6 antagonists with proteasome inhibitors | |
| JP2019216721A (ja) | 抗−ｔｎｆ抗体、組成物、方法および使用 | |
| RU2015134562A (ru) | Лечение остеоартрита и боли | |
| CA2496523A1 (en) | Human antihuman interleukin-6 antibody and fragment of the antibody | |
| CN101899113A (zh) | 针对血管内皮生长因子的人源化抗体 | |
| EP4166568B1 (en) | Anti-human interleukin 23 monoclonal antibody and application thereof | |
| EP3105247B1 (en) | Scfv antibody library | |
| JP2012503977A (ja) | ヒトｉｌ１７に対する抗体およびその使用 | |
| JP7680078B2 (ja) | 抗ヒトインターフェロンα受容体１モノクローナル抗体及びその使用 | |
| JP2024105229A5 (enExample) | ||
| CN104231080B (zh) | 全人源抗人白介素17a单链抗体 | |
| CN108368167A (zh) | Cd131结合蛋白及其应用 | |
| WO2023036127A1 (zh) | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 | |
| KR101900878B1 (ko) | TNF-α 결합 압타머 및 그것의 치료적 용도 | |
| CN116284401B (zh) | 人源抗il-1r3抗体及其应用 | |
| CN114829398B (zh) | 对人il-13具有结合特异性的抗体 | |
| WO2023152204A8 (en) | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof | |
| CN107857816B (zh) | 一种抗干扰素α-2b纳米抗体及其应用 | |
| US20040214242A1 (en) | Method for the isolation of large variances of specific molecules for a target molecule from phagemid gene libraries, and a test kit | |
| Keane et al. | Chemokines and Cytokines in ARDS |